Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alfresa HoldingsARHCF 82 Earnings Yield (Joel Greenblatt) % is 20.62% as of Mar. 2026, which is 16% above its 10-year median of 17.85. GuruFocus rates ARHCF with a GF Score™ of 82/100 and a GF Value™ of $12.24 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 122 Medical Distribution companies, Alfresa Holdings ranks better than 95.9% on this metric.
Alfresa Holdings's Enterprise Value for the quarter that ended in Mar. 2026 was $1,168 Mil.
Alfresa Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $385 Mil. Alfresa Holdings's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 20.62%.
The historical rank and industry rank for Alfresa Holdings's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
ARHCF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 9.85 Med: 17.85 Max: 35.22
Current: 26.53
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Alfresa Holdings was 35.22%. The lowest was 9.85%. And the median was 17.85%.
ARHCF's Earnings Yield (Joel Greenblatt) % is ranked better than 95.9% of 122
companies
in the Medical Distribution industry
Industry Median: 6.065
vs ARHCF: 26.53
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Alfresa Holdings's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 11.10%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Alfresa Holdings Earnings Yield (Joel Greenblatt) % Related Terms
Alfresa Holdings Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Alfresa Holdings's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Alfresa Holdings's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alfresa Holdings Earnings Yield (Joel Greenblatt) % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Alfresa Holdings's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Alfresa Holdings's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Alfresa Holdingss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
Alfresa Holdings's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $385 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 20.62% mean?
Alfresa Holdings (ARHCF) has a Earnings Yield (Joel Greenblatt) % of 20.62% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Alfresa Holdings and its competitors. This is 16% above median its historical median of 17.85. Over the past decade, Alfresa Holdings' Earnings Yield (Joel Greenblatt) % has ranged from 9.85 to 35.22. According to the industry distribution chart, Alfresa Holdings ranks #5 out of 122 companies in the Medical Distribution industry, placing it in the top 4.1%.
Is Alfresa Holdings' Earnings Yield (Joel Greenblatt) % too high?
Alfresa Holdings' current Earnings Yield (Joel Greenblatt) % of 20.62% is 16% above median its 10-year median of 17.85. Over the past 10 years, this metric has ranged from a low of 9.85 to a high of 35.22. The Medical Distribution industry median Earnings Yield (Joel Greenblatt) % is 6.07. Alfresa Holdings' value of 20.62% is 240% above this industry median. Based on the distribution chart, Alfresa Holdings ranks #5 out of 122 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Alfresa Holdings has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alfresa Holdings' Earnings Yield (Joel Greenblatt) % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Alfresa Holdings ranks #5 out of 122 companies for Earnings Yield (Joel Greenblatt) %. This places Alfresa Holdings in the top 4% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 6.07. Alfresa Holdings' value of 20.62% is 240% above this benchmark. Historically, Alfresa Holdings' own Earnings Yield (Joel Greenblatt) % has ranged from 9.85 to 35.22 over the past decade. While the company's 10-year median is 17.85 vs. the industry median of 6.07, Alfresa Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Distribution company?
The median Earnings Yield (Joel Greenblatt) % among Medical Distribution companies is 6.07, based on 122 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alfresa Holdings's current Earnings Yield (Joel Greenblatt) % of 20.62% is 240% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Alfresa Holdings and its competitors. For the Medical Distribution industry, the median Earnings Yield (Joel Greenblatt) % is 6.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alfresa Holdings's current Earnings Yield (Joel Greenblatt) % is 20.62%, which is 16% above median its own 10-year median of 17.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alfresa Holdings stock overvalued right now?
Based on GuruFocus' analysis, Alfresa Holdings (ARHCF) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.24, compared to a current price of $14.00 — trading 14.4% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 20.62%, which is 16% above median its 10-year median of 17.85 and 240% above the Medical Distribution industry median of 6.07. Alfresa Holdings' overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Alfresa Holdings (ARHCF), the current Earnings Yield (Joel Greenblatt) % is 20.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alfresa Holdings (ARHCF) Overvalued in 2026?
Based on GuruFocus' analysis, Alfresa Holdings stock appears to be overvalued.
The current stock price of $14.00 is trading 14.4% above its estimated GF Value™ of $12.24.
GuruFocus considers Alfresa Holdings to be Modestly Overvalued.
Key valuation signals for ARHCF:
Earnings Yield (Joel Greenblatt) %: 20.62% (16% above median its 10-year median of 17.85)
GF Value™: $12.24 vs. price of $14.00 (14.4% above fair value)
Industry Position: 240% above the Medical Distribution median (#5 of 122)
No single metric tells the full story. See the ARHCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alfresa Holdings Corp is engaged in the pharmaceutical distribution and related businesses. The company operates through four reportable segments: Wholesale business of medical drugs, Self-Medication Wholesale Business, Pharmaceutical Manufacturing Business, and Medical-Related Business. Its operations include the wholesale of ethical and over-the-counter pharmaceuticals, the manufacture and sale of pharmaceuticals, medical testing reagents, and medical equipment, as well as the operation of dispensing pharmacies.
82GF Score
Get the complete analysis for ARHCF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARHCF has been successfully added to your 
